Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
Recent Articles
RELATED ARTICLES
-
PegBio aims to bulk up its finances to deliver weight-loss drugs
- Innogen Pharma jostles for a slice of the weight-loss market
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
